Session » Systemic Sclerosis & Related Disorders – Clinical Poster II

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1652

Anticentromere Antibody Levels and Isotypes Associate with Disease Severity in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1631

Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1642

Automated Nailfold Capillary Counting System (AUTOCAPI) in Systemic Sclerosis Patients with Different Capillaroscopic Patterns

9:00AM-11:00AM: Abstract Number: 1650

Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)

9:00AM-11:00AM: Abstract Number: 1641

Change in Calcinosis over 1 Year Using the SCTC Radiologic Scoring System for Calcinosis of the Hands in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1645

Comparison of Automated Capture and Analysis System of Sublingual Microvessels and Nailfold Videocapillarscopy for Microvascular Assessment in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1634

Comparison of Different Pulmonary Hypertension Screening Algorithms in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1630

Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1635

Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1640

Cutaneous and Musculoskeletal Clinical Characterization of a Cohort of Patients with Chronic Graft-versus-host Disease

9:00AM-11:00AM: Abstract Number: 1636

Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial

9:00AM-11:00AM: Abstract Number: 1644

Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial

9:00AM-11:00AM: Abstract Number: 1643

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use

9:00AM-11:00AM: Abstract Number: 1653

Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study

9:00AM-11:00AM: Abstract Number: 1639

Endoscopic Findings in a Scleroderma Cohort with and Without Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1654

Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1632

Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1656

Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial

9:00AM-11:00AM: Abstract Number: 1655

Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1658

Impact of Visceral Involvement in the Characterization and Prognosis of Patients Without Skin Involvement Classified as Systemic Sclerosis (SSc) According to 2013 ACR/EULAR Criteria in a Large Single Cohort

9:00AM-11:00AM: Abstract Number: 1646

Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution

9:00AM-11:00AM: Abstract Number: 1659

Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1628

Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom

9:00AM-11:00AM: Abstract Number: 1651

Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers

9:00AM-11:00AM: Abstract Number: 1649

Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II

9:00AM-11:00AM: Abstract Number: 1633

Relationship Between YKL-40, VEGF, and IL-5 in Borderline mPAP and Pulmonary Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1657

Sarcopenia in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1660

Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?

9:00AM-11:00AM: Abstract Number: 1638

Sexual Health in 60 Female Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1629

Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience

9:00AM-11:00AM: Abstract Number: 1648

Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression

9:00AM-11:00AM: Abstract Number: 1637

The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy

9:00AM-11:00AM: Abstract Number: 1647

The Collaborative National Quality and Efficacy Registry for Scleroderma: Data Completion Outcomes from a Multicenter United States Cohort Using Guideline-Based Registry Practices

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].